Indian pharmaceutical company
Natco Pharma is an Indian multinational pharmaceutical company based in Hyderabad. The company manufactures finished dosage formulations active pharmaceutical ingredients and Agro chemical products.[5] It is a major producer of branded oncology medicines[6] cardiology, diabetology and other pharma specialty drugs.[7] The company specialises in producing complex medicines at affordable prices.[8][9] NATCO is a science driven company and focuses on limited competition molecules in the US.
[10][11]
History
- NATCO Pharma was founded in the year 1981 by V C Nannapaneni
- In 1983 operations commenced at manufacturing facility at Nagarjunasagar, Telangana
- In 1986 Chemical division commenced at Mekaguda, Telangana
- In 2008, NATCO Pharma filed its first paragraph IV filing in the US with the USFDA, [12]
- In 2012, NATCO Pharma obtained compulsory license to produce a cheaper and generic version of Bayer's anti-cancer medication Nexavar.[7]
- In the United States, it launched influenza medication Tamiflu with marketing partner Alvogen, multiple sclerosis treatment drug glatiramer acetate in partnership with Mylan, and hepatitis C drugs under a licensing agreement with Gilead Sciences.[12]
- In 2016, NATCO Pharma launched the first Tamiflu capsule in the US market.[13]
- In 2019, NATCO Pharma initiated work on green-field manufacturing facilities for producing niche agrichemical products in Nellore district, Andhra Pradesh.[14]
- In 2022 Crop Health Sciences division launched Chlorantraniliprole (CTPR) based products.
- NATCO launched the first generic version of Revlimid in the US market
- For the financial Year 2024, NATCO recorded its highest ever revenue, Earnings Before Interests Tax Depreciation and Amortization and profit after tax.
External links
References